<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789464</url>
  </required_header>
  <id_info>
    <org_study_id>H-23187</org_study_id>
    <nct_id>NCT00789464</nct_id>
  </id_info>
  <brief_title>Probiotics for Girls With Recurring Urinary Tract Infections</brief_title>
  <official_title>H-23187: Probiotic Prophylaxis Against Recurrent Pediatric Urinary Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probiotics are dietary supplements containing potentially beneficial bacterial strains such&#xD;
      as Lactobacillus. The safety of oral administration of probiotics has been demonstrated in&#xD;
      hundreds of studies using adults over the last 30 years. Very few studies have been conducted&#xD;
      with children. UTI in girls occur when virulent bacteria migrate from the rectum and colonize&#xD;
      the vagina and peri-urethral mucosa, thus gaining access to the bladder.&#xD;
&#xD;
      This study will randomize girls to ARM A (probiotics + placebo) and ARM B (antibiotics +&#xD;
      placebo) to determine if UTIs are decreased when the probiotics are given.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn by PI&#xD;
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be the rates of bacteriuria among the subjects and the comparison of the two arms.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Recurrent Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Probiotics drops plus placebo elixir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TMP/SMZ elixir plus placebo drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM 17938</intervention_name>
    <description>DSM 17938 drops (10^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.</description>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimethoprim/sulfamethoxazole</intervention_name>
    <description>Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.</description>
    <arm_group_label>ARM B</arm_group_label>
    <other_name>TMP/SMZ, Bactrim, Septra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Girls age 1 through age 17 years of age&#xD;
&#xD;
          -  Must have had at least 3 symptomatic UTI, uncomplicated or complicated, in the year&#xD;
             preceding study inclusion or already using any form of prophylaxis to prevent&#xD;
             recurrences of UTI&#xD;
&#xD;
          -  Must have had at least 3 symptomatic urinary tract infections in the year before the&#xD;
             start of the prophylaxis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prior adverse reaction to sulfa drugs or sulfamethoxazole/trimethoprim&#xD;
&#xD;
          -  Known immunosuppression i.e., transplant recipients or children with congenital&#xD;
             immunodeficiencies&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  Untreated HIV infection&#xD;
&#xD;
          -  Use of high dose corticosteroids for autoimmune diseases or post-organ&#xD;
             transplantation. Inhaled corticosteroids or oral steroids for asthma are allowed.&#xD;
&#xD;
          -  Malnutrition&#xD;
&#xD;
          -  Patients with a history of sulfamethoxazole/trimethoprim-resistant UTI will be&#xD;
             excluded from the study&#xD;
&#xD;
          -  Patients with renal insufficiency, liver insufficiency, or cardiopulmonary disease&#xD;
             requiring medication will be excluded from the study&#xD;
&#xD;
          -  Patients with known anemia will be excluded from the study&#xD;
&#xD;
          -  Patients taking medications that may interact with sulfamethoxazole/trimethoprim will&#xD;
             be excluded from the study&#xD;
&#xD;
          -  Patients taking other probiotics will be excluded from the study&#xD;
&#xD;
          -  Patients already taking prophylactic antibiotics will be excluded from the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 10, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>David Roth</investigator_full_name>
    <investigator_title>Professor, TCH Urology</investigator_title>
  </responsible_party>
  <keyword>Urinary Tract Infection</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Dietary Supplements</keyword>
  <keyword>Bacteriuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

